Abstract #1306 - 8:45, Monday, December 7, 1998 - Room B214-218 TREATMENT OF MULTIPLE MYELOMA MARKED ANTI-TUMOR EFFECT FROM ANTI-ANGIOGENESIS (AA) THERAPY WITH THALIDOMIDE (T) IN HIGH RISK REFRACTORY MULTIPLE MYELOMA (MM) S. Singhal, J. Mehta, P. Eddlemon*, P. Gray*, J. Cromer*, R. Desikan*, D. Ayers*, D. Siegel, N. Munshi, E. Anaissie, H. Kantarjian, J. Zeldis*, B. Barlogie
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas; University of Texas MD Anderson Cancer Center, Houston, Texas; Celgene Corporation, Warren, New Jersey, USA
The abstract concludes:
"In conclusion, T [thalidomide] has remarkable anti-tumor activity in advanced and high risk MM, justifying its incorporation into combination chemotherapy trials (D.T. PACE-Dex, T, cisplatin, 1 Adria, CTX, VP16) which has induced 3 true CR's [complete remissions] after 1 cycle among 5 currently evaluable patients."